Pegfilgrastim biosimilar - Fresenius Kabi

Drug Profile

Pegfilgrastim biosimilar - Fresenius Kabi

Alternative Names: MSB-11455

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck KGaA
  • Developer Fresenius Kabi
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 22 Aug 2017 Phase-I clinical trials in Cancer (In volunteers) in Australia (SC) (NCT03251248)
  • 21 Aug 2017 Phase-I clinical trials in Cancer (In volunteers) in New Zealand (SC) (NCT03251339)
  • 21 Aug 2017 Merck KGaA plans a phase I trial in Healthy subjects in August 2017 (NCT03251248)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top